Lilly reports one-year histologic outcomes in Phase 3 study of ...
3 days ago · Data show more patients treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab. New data are first-of-its-kind analysis of microscopic mucosal resolution that go beyond endoscopy, setting a new potential standard for the evaluation of therapeutic response. INDIANAPOLIS, Oct. 14, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced data ...
More Patients On Eli Lilly's Mirikizumab Achieved Histologic …
3 days ago · The data showed that more patients achieved histologic response were observed with mirikizumab at Week 52 in the overall population (58.2% versus 48.8%; p=0.0075). Also Read: Novo Nordisk, Eli ...
Lilly reports one-year histologic outcomes in Phase 3 study of ...
3 days ago · Mirikizumab is an IL23p19 antagonist that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. Inflammation due to the overactivation of the IL-23 ...
Lilly reports one-year histologic outcomes in Phase 3 study of ...
3 days ago · Patients randomized to mirikizumab were administered 900 mg of mirikizumab intravenously every four weeks from Week 0-12, then 300 mg subcutaneously every four weeks from Weeks 12-52.
News Release - Eli Lilly and Company
Oct 26, 2023 · Omvoh (mirikizumab-mrkz) is an interleukin-23p19 antagonist indicated for the treatment of moderately to severely active ulcerative colitis in adults. Omvoh selectively targets the p19 subunit of IL-23 and inhibits the IL-23 pathway.
News Release - Eli Lilly and Company
May 21, 2024 · Patients taking mirikizumab achieved combined Week 52 clinical remission and endoscopic response at nominally statistically significant higher rates compared to patients on ustekinumab (34.4% versus 27.9%), with greater difference …
Lilly's Mirikizumab Helped Patients with Crohn's Disease Achieve …
Oct 12, 2023 · Mirikizumab demonstrated clinical remission and endoscopic response for patients with moderately to severely active Crohn's disease through 52 weeks
FDA Approves Mirikizumab, a Promising Induction and …
Oct 27, 2023 · The U.S. Food and Drug Administration (FDA) approved mirikizumab, on October 26, 2023, a highly effective new treatment for ulcerative colitis (UC), offering a new option to patients battling this chronic and debilitating inflammatory bowel disease.
Lilly reports one-year histologic outcomes in Phase 3 study of ...
3 days ago · Mirikizumab has additional ongoing trials in UC, including a study in pediatric patients (NCT05784246) and a study to evaluate the long-term efficacy and safety of mirikizumab in adults (NCT03519945).
Lilly Reports 1-year Histologic Data From Phase 3 VIVID-1
3 days ago · (RTTNews) - Eli Lilly and Company (LLY) Monday announced 1-year histologic data from the Phase 3 VIVID-1 study of mirikizumab in people with Crohn's disease, a type of inflammatory bowel disease.
- Some results have been removed